|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
68
|
March 20, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
312
|
March 19, 2026
|
|
Request for analytical method support – N-nitroso-piperidine in LVP elastomeric packaging (E&L study)
|
|
0
|
118
|
March 19, 2026
|
|
Physical form of nitrosamine Standards
|
|
1
|
119
|
March 18, 2026
|
|
Differences in Physical Form of Nitrosamine Reference Standards: USP vs. Other Suppliers
|
|
2
|
155
|
March 18, 2026
|
|
Scientific Clarification Request on Analytical Approach for Nitrosamine Determination in Quetiapine Oral Suspension
|
|
3
|
234
|
March 17, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
2
|
189
|
March 17, 2026
|
|
MEGLUMINE (Methylglucamine)
|
|
28
|
3714
|
March 16, 2026
|
|
EMA Q&A Appendix 1 update posted on 13 March 2026
|
|
1
|
421
|
March 16, 2026
|
|
Challenges in developing an analytical method for N‑nitroso‑ambroxol -
|
|
1
|
146
|
March 14, 2026
|
|
Testing of N-nitroso-cinacalcet
|
|
8
|
1014
|
March 14, 2026
|
|
Limit Test for NDSRI Risk Assessment?
|
|
3
|
183
|
March 13, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
3
|
266
|
March 12, 2026
|
|
Navigating the complexities in characterization of NDSRIs using advanced analytical techniques-Pub
|
|
2
|
238
|
March 12, 2026
|
|
Challenges in developing an analytical method for N‑nitroso‑ambroxol
|
|
3
|
211
|
March 11, 2026
|
|
Register for Free Webinar- Australia and New Zealand: Nitrosamines Impurities 19 March 2026
|
|
0
|
214
|
March 10, 2026
|
|
Register for Quality Hour- Japan Edition: Nitrosamines Impurities 18 March 2026
|
|
0
|
212
|
March 8, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
21
|
4736
|
March 7, 2026
|
|
Nitrosamine analysis in suspension dosage forms
|
|
5
|
259
|
March 6, 2026
|
|
Nitrosamine Risk in Trospium chloride tablets
|
|
2
|
156
|
March 4, 2026
|
|
The Bench Mark dose (BMD) - Recorded full two day training FREE
|
|
4
|
376
|
March 4, 2026
|
|
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals
|
|
33
|
3964
|
February 28, 2026
|
|
Question about N-Nitroso nicardipine
|
|
5
|
783
|
February 28, 2026
|
|
N-Nitrosodibenzylamine infusion bags
|
|
0
|
117
|
February 27, 2026
|
|
Moxonidine Nitrosamines
|
|
6
|
273
|
February 25, 2026
|
|
Podcast: Reducing Nitrosamines and Driving Patient Safety
|
|
0
|
139
|
February 23, 2026
|
|
NDSRI growth with respect to age
|
|
11
|
417
|
February 23, 2026
|
|
Nitrosamine Risk Assessment on DETA
|
|
0
|
136
|
February 22, 2026
|
|
EMA proposes GMP update to EudraLex to address nitrosamine impurities
|
|
14
|
1075
|
February 20, 2026
|
|
Nitrites/Nitrosamines: The impacts on analytics, but not only
|
|
0
|
181
|
February 17, 2026
|